OncoHost

12/11/2025

🚭 Myth vs. Reality: Unveiling Lung Cancer Misconceptions 🫁

At OncoHost, we’re committed to cutting through the noise and elevating the conversation around lung cancer - because informed decisions start with accurate information.

12/10/2025

👉 Did you know?
Resistance to in non-small cell lung cancer ( ) isn't random. It’s biological. And OncoHost is uncovering the why behind it.

Our PROphet® platform uses a set of 388 resistance-associated proteins (RAPs) to predict the clinical benefit to immune checkpoint inhibitors.

A recent study showed that these RAPs are linked to key hallmarks—like invasion, metastasis, and immune suppression—and may even serve as drug targets. This opens the door to more precise, personalized treatment strategies for patients who might otherwise face resistance.

RAP profiles help us understand outcomes - before treatment begins.

Your insights. Amplified. By PROphet®.

Learn more about RAPs here:

Background Immune checkpoint inhibitors (ICIs) have shown substantial benefit for patients with advanced non-small cell lung cancer (NSCLC). However, resistance to ICIs remains a major clinical challenge. Here, we perform a comprehensive bioinformatic analysis of plasma proteomic profiles to explore...

12/09/2025

📣 Thank you, Mobile Health Times, for spotlighting our latest achievement!

We’re honored to be featured in your coverage of OncoHost’s Gold win in the 2025 Merit Awards for Healthcare – Technology Solution of the Year.

Read the full piece here:
https://bit.ly/4puV5Xs

Awards and Recognition OncoHost Wins Gold in 2025 Merit Awards for Healthcare ByCharlie Thomas December 8, 2025December 8, 2025 PROphet® Platform Recognized as Technology Solution of the Year for Advancing Precision Oncology OncoHost, a biotechnology company focused on precision oncology through pr...

12/04/2025

🏆 Gold Winner!

We are excited to announce that OncoHost has been awarded 'Technology Solution of the Year' in the 2025 Merit Awards for Healthcare for our PROphet® precision-oncology platform.

AI + = a new era of predictive, personalized cancer care.

🔗 Learn more: https://prn.to/4q8sZBp

12/03/2025

PROphetNSCLC® provides insights to answer the question: Which first-line therapy is more likely to improve overall survival of the patient?

✔️ One blood draw
✔️ Results 8 days from sample receipt at our CLIA-certified and CAP-accredited lab
✔️ Guides first-line treatment decisions

Transform complex data into actionable guidance to deliver care that's truly individualized: https://bit.ly/432ksp4

12/01/2025

📣 New Study Links Tattoos to Higher Melanoma Risk

A new Swedish study reports that people with tattoos may have a 29% higher risk of developing melanoma. The research found no increased risk for squamous cell carcinoma, and results remained consistent even after accounting for UV exposure, skin type, and lifestyle factors.

While the study does not prove causation, it highlights the need for continued research into tattoo ink, chronic inflammation, and long-term health effects.

https://bit.ly/4pIkb4R

For now, the guidance remains unchanged:
☀️ Protect your skin from UV radiation
👀 Monitor for new or changing moles
🩺 Seek medical evaluation when in doubt

No increased risk was found for another UV-related skin cancer, squamous cell carcinoma.

11/28/2025

Odds are, someone you know will be diagnosed with in their lifetime.

It's not just a statistic—it's your friend, your colleague, your loved one. This disease doesn't discriminate.

It's time we all become advocates. Know the signs, support screening, and stand with those fighting.

11/27/2025

Happy to all! We are grateful for our dedicated team, supportive partners, and the patients who inspire our work every day. May your day be filled with hope, health, and gratitude.

11/26/2025

🌟 Employee Spotlight 🌟

This month, we’re excited to shine the spotlight on Colin Hogan, a key member of our U.S. sales team and a true champion of our mission to transform cancer care.

Colin brings a rare blend of strategic thinking, field experience, and genuine empathy to every interaction. Whether he’s partnering with oncologists to integrate PROphet® into their workflows or collaborating cross-functionally to drive seamless ex*****on, Colin consistently goes the extra mile to ensure that physicians feel supported and patients stay at the center of every decision.

11/25/2025

We’re excited to share the strong media traction following our announcement that PROphetNSCLC® has received a laboratory permit from the New York State Department of Health Wadsworth Center.

This milestone continues to reinforce OncoHost’s position at the forefront of precision oncology, and the industry is taking notice. Over the past month, our news has been featured across leading life-sciences and healthcare outlets, highlighting the growing demand for biologically explainable, AI-powered decision support in cancer care.

11/24/2025

Lung cancer's devastating impact often flies under the radar. It claims 3x more women's lives than breast cancer in the U.S., and 3x more men's lives globally than prostate cancer. Let's raise awareness, push for better screening, and fund critical research. Every breath counts in this fight.

11/20/2025

Still celebrating this milestone! 🏆

Two weeks after being named “Proteomics Innovation of the Year,” we’re as energized as ever. This recognition underscores our commitment to advancing precision oncology through proteomics, AI, and deep biological insight.

Proud of our team. Grateful for our partners. Inspired for what’s next. 💙